News and Analysis | Published:

Pharma pumps up anti-tau Alzheimer pipeline despite first Phase III failure

Nature Reviews Drug Discovery volume 15, pages 591592 (2016) | Download Citation

AbbVie, Bristol-Myers Squibb, Genentech, Janssen and Merck & Co. have all advanced anti-tau candidates into Phase I trials in the hunt for drugs that can modify the course of Alzheimer disease.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

About this article

Publication history




  1. Search for Asher Mullard in:

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing